Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing Haduvio, an oral therapy for chronic cough and related respiratory conditions. The company’s work centers on clinical development, regulatory approval, and eventual commercialization of Haduvio in the United States and through partners outside the U.S.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical-stage development of Haduvio across respiratory cough indications.
Activities supporting FDA and other regulatory submissions for Haduvio.
Planned U.S. and ex-U.S. commercialization of approved Haduvio products.
Asiakkaat
Trevi does not currently sell commercial products; its eventual customers would be physicians, patients, and payors in respiratory disease markets. If approved, Haduvio would be prescribed by pulmonologists and other specialists treating IPF, non-IPF ILD, or refractory chronic cough, with reimbursement decisions made by third-party payors. Outside the U.S., commercialization would likely rely on collaboration or distribution partners rather than a direct sales force.
Specialists who would prescribe Haduvio for IPF and non-IPF ILD-related chronic cough.
Pulmonologists and allergists treating RCC patients who have failed other therapies.
Insurers and government payors that decide coverage and reimbursement levels.
End users of the therapy, especially those with IPF, non-IPF ILD, or RCC.
Potential collaborators that would help market and distribute Haduvio outside the U.S.
Strategia
Trevi’s strategy is to advance Haduvio through late-stage clinical development, secure regulatory approval, and build a focused specialty commercial model in the U.S. The company is also pursuing intellectual property protection, manufacturing readiness, and reimbursement access while using partners for markets outside the U.S. Its near-term direction is defined by clinical execution and capital allocation to support multiple cough indications.
Approval depends on demonstrating safety and efficacy in target cough populations.
A focused specialty sales model is needed if the product is approved.
Coverage and reimbursement will determine whether the product can be adopted at scale.
Patent protection and reliable manufacturing support long-term commercial value.
Maantiede
Trevi is headquartered in the United States and expects initial commercialization of Haduvio to be U.S.-focused. The company also expects to use third-party collaboration, distribution, and marketing arrangements outside the U.S., which makes international reach dependent on partners and local regulatory approvals. Its clinical and commercial exposure is therefore concentrated in the U.S., with future expansion tied to ex-U.S. partnering.
Riskit
Trevi is a clinical-stage company with no product sales, so its value depends on successful development, approval, and commercialization of Haduvio. Key risks include clinical trial failure, regulatory delays, reimbursement uncertainty, manufacturing dependence on third parties, and the need for substantial additional capital. As with most biopharma developers, patent protection, safety findings, and market acceptance are also critical to future success.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Haduvio must prove safety and efficacy across target cough indications before approval.
Kohdistuu - Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea
FDA and other authorities may require more data, delay approval, or reject applications.
Kohdistuu - Financing riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company expects to fund operations through external capital until product revenue exists.
Kohdistuu - Reimbursement and pricing riskVaikutus: KorkeaTodennäköisyys: Matala
Payors may restrict coverage or require pricing concessions, limiting adoption.
Kohdistuu: U.S. and international market access
- Manufacturing and third-party dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Drug substance and finished product supply rely on external vendors and cGMP compliance.
Kohdistuu - Intellectual property riskVaikutus: KeskitasoTodennäköisyys: Matala
Patent scope, validity, and foreign protection affect exclusivity and long-term value.
Kohdistuu: U.S. and foreign patent portfolios
Kirjanpito
Harkinnanvaraiset erätClinical trial and CRO costs are recognized based on estimates of work performed, affecting quarterly expense timing.
Vaikutus: Can shift reported R&D expense between periods
Employee and consultant equity awards create non-cash expense that can be significant for a development-stage company.
Vaikutus: Affects operating loss and non-cash reconciliation
Cash invested in marketable securities creates fair value and accretion impacts in other income and cash flow.
Vaikutus: Can affect reported investment gains/losses
Operating leases for office or research space require right-of-use asset and liability recognition.
Vaikutus: Affects balance sheet and operating expense presentation
If Haduvio is commercialized, gross-to-net reserves, rebates, and payor deductions will become important estimates.
Vaikutus: Will affect net product revenue and margins
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Tvardi Therapeutics, Inc.
TVRD · Pharmaceutical Preparations
Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers.
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Cocrystal Pharma, Inc.
COCP · Pharmaceutical Preparations
Traws Pharma, Inc.
TRAW · Pharmaceutical Preparations
BioVie Inc
BIVIW · Pharmaceutical Preparations
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
Päivitetty: 24.9.2026